Table 2

Multivariate linear regression analyses for associations between BP, BMI and P wave duration

Model 1Model 2Model 3Model 4
βP valueβP valueβP valueβP value
SBP, mm Hg0.03<0.0010.03<0.0010.02<0.0010.020.002
DBP, mm Hg0.11<0.0010.09<0.0010.09<0.0010.09<0.001
BMI, kg/m20.44<0.0010.36<0.0010.25<0.0010.25<0.001
Age, year0.050.0010.050.0010.050.0010.050.003
Male (1) vs. Female (0)3.11<0.0012.55<0.0012.02<0.0011.98<0.001
FBG, mmol/L0.040.6140.040.6030.040.608
TC, mmol/L0.830.0070.730.0180.710.023
TG, mmol/L−0.050.682−0.020.843−0.020.899
LDL-C, mmol/L−0.360.312−0.210.573−0.170.647
HDL-C, mmol/L−1.96<0.001−1.81<0.001−1.81<0.001
SUA, mg/dL0.050.6460.010.9140.000.994
Current smoker (yes/no)0.020.9490.130.6630.100.751
Current drinker (yes/no)1.210.0011.190.0021.180.002
Anti-arrhythmic medication (yes/no)−1.830.263−2.540.125−2.600.116
Anti-hypertensive medication (yes/no)1.250.0011.170.0031.150.003
Mitral stenosis/regurgitation (yes/no)−0.040.968−0.940.356−1.120.273
History of MI (yes/no)−0.160.891−0.300.805−0.330.785
History of HF (yes/no)−1.400.314−1.840.189−1.890.179
LAD, cm2.83<0.0012.66<0.001
LVMI, g/m20.010.208
  • Model 2: additional variables including FBG, plasma lipids, SUA, smoking, drinking, education, income, anti-arrhythmic medication, anti-hypertensive medication, mitral stenosis/regurgitation, and history of MI and HF; model 3: additional variable LAD; model 4: additional variable LVMI.; Note, model 1: SBP, DBP, BMI, age, gender and race in the multivariate regression.

  • BMI, body mass index; BP, blood pressure; CNY, China Yuan; DBP, diastolic blood pressure; FBG, fasting blood glucose; HDL-C, high-density lipid cholesterol; HF, heart failure; IAB, interatrial block; LAD, left atrial diameter; LAE, left atrial enlargement; LDL-C, low-density lipid cholesterol; LVH, left ventricular hypertrophy; LVMI, left ventricular mass index; MI, myocardial infarction; SBP, systolic blood pressure; SUA, serum uric acid; TC, total cholesterol; TG, triglycerides.